Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Letters to the Editor

Staff  |  Issue: January 2008  |  January 1, 2008

In “Know Your Unknown Unknowns,” (October 2007 TR, p. 6), we asked for your thoughts on whether or not to administer steroids post-surgery for a woman with giant cell arteritis (GCA) of the aorta. (See patient description below). We’ve published a selection of those responses here, and we want to thank everyone who wrote in. Keep those letters coming!—The Editors

Mixed Views on Steroid Use

No doubt that steroids were needed in this case. The key question: Were the margins of the graft involved or free of giant cell inflammation? If the inflammatory process was extensive at the graft-tissue interface, I would be concerned about healing at the interface. If the interface was clear and the patient would be followed closely for amaurosis or other ominous symptoms, then I would be more likely to be patient on starting steroids. Do no harm.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Patient

  • Woman in her 70s with age-related medical conditions and ill-defined chest pain;
  • Aneurysm of the ascending thoracic aorta treated surgically with a graft; and
  • Pathologically diagnosed GCA of the aorta.

Now the question is how long does it take normally for an aortic graft-tissue interface to heal in a 70-year-old patient? We now know that atherosclerosis is an inflammatory process and that many of these grafts will go into an area of inflammatory atheromatous aorta—at times flagrantly inflamed. Yet from what I gather they usually heal. This patient may have had both giant cell aortitis and inflammatory atherosclerosis.

My guess is that steroids were held, the graft healed, and steroids were started later with no end point to follow. A PET scan can show active inflammation in giant cell aortitis and smaller arteries and may provide some additional information about extent and activity.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Robert Thoburn, MD,
adjunct clinical assistant professor of rheumatology,
University of Florida College of Medicine,
Gainesville

 

I hate to say that the surgeon is probably right and the rheumatologist wrong in this case. Why? The vasculitis (of the aorta) was found by accident (vague abdominal pains). No other stigmata of vasculitis whatsoever were found on physical or imaging examination. This was probably an isolated vasculitis of the aorta.

Therefore—although this sounds a bit weird—surgery could have cured her vasculitis, and steroids can be withheld.

On the other hand, if there were other symptoms, such as headache or blurred vision, or stigmata like elevated erythrocyte sedimentation rate (ESR) (which she did not have, we were told), then we’d have cause to seriously consider systemic therapy.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Conditions Tagged with:aortaatherosclerosisgiant cell arteritis (GCA)inflammationLettersSteroids

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Updates on Giant Cell Arteritis

    March 19, 2018

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

    Giant Cell Arteritis Challenging to Diagnose, Manage

    March 1, 2015

    Common form of primary vasculitis difficult to identify, treat, but latest research suggests potential new therapeutic targets

    Case Report: Giant Cell Arteritis-Related Stroke

    September 10, 2023

    Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences